



KEY ADVANCES PRACTICE ADVANCE

Anticoagulant Reversal Strategies in the Emergency Department

Updated January 2026

Why is this topic important? Direct oral anticoagulants (DOACs) are used increasingly for various indications. Initially, these agents were approved for use without a corresponding strategy to stop serious bleeding in patients taking DOACs. Emerging data and policy guidelines are now available to reverse life-threatening or critical-site bleeding.

How will this change my clinical practice? Consensus guidelines promote standardized approaches to deciding which patients on DOACs with major bleeding are likely to benefit from reversal and when anticoagulation can be restarted after minor bleeding.

Synopsis Focus Points: All DOACs may be reversed with prothrombin complex concentrates (PCCs). Specific reversal agents are recommended if available.

Background:

DOACs are used to prevent and treat thromboembolic-associated events, such as stroke, venous thromboembolism, and pulmonary thromboembolism. Their main advantage over warfarin is that routine blood monitoring is not necessary. Bleeding is the most common complication, and specific laboratory tests are typically unavailable or unhelpful.

A multidisciplinary panel suggested anticoagulant reversal strategies in the emergency department (ED). (1) They identified three critical considerations for managing the bleeding patient taking an anticoagulant: 1) is this a life-threat? 2) is this a critical site for complications? and 3) what are the specifics of the agent, dose, and time taken?

Life-threatening bleeding is defined as a hemoglobin drop of ≥ 5 g/dL from previous, uncontrolled bleeding requiring procedural intervention, or hemodynamic instability. **Critical sites for bleeding** include airway, brain, pericardium, aorta, spine, eye, and closed space at risk for compartment syndrome.

Many patients have **major (serious) bleeding** rather than imminently life-threatening presentations. Major bleeding is defined as a hemoglobin drop of ≥ 2 g/dL from previous or one that requires a blood transfusion of ≥ 2 units of packed red blood cells. (2)

Life-threatening bleeding or critical site bleeding events should be treated with a reversal agent in addition to supportive measures and other potential therapeutic interventions (surgical, interventional radiology, or endoscopic). If the DOAC has an available reversal agent, it should be used as a first-line strategy. (1,2,3) A specific reversal agent included is idarucizumab for dabigatran. As of December 2019, the FDA released guidance that the thrombotic risks and increased mortality outweigh the benefit of andexanet alfa, no longer recommending the clinical use of this product. (4)


If these are not available or the patient does not know which DOAC they take, then **PCC** should be given. (1,2,3) Currently, only 4-factor PCC Kcentra is US Food and Drug Administration–approved for the reversal of major or life-threatening bleeding in patients taking warfarin. Kcentra is frequently used off-label for the reversal of DOACs and does not carry an increased thromboembolic risk. (5)

Fresh frozen plasma is an alternative to PCCs if unavailable, but it requires time to defrost (typically 2 hours), may involve large volumes to be administered, and has limited data to support its use for DOAC reversal.

Hemodynamically stable patients with major bleeding should have their agent held and the source of the bleeding addressed. Pressure should be applied if applicable and consideration should be given to a procedural intervention (i.e., interventional radiology or surgery) if appropriate. (2)

Minor bleeding (e.g., nose bleeds, bruising) may be monitored, the next dose held, and reassessment made as to restarting the medication. (3,6) Restarting the DOAC may be considered after a minor bleeding episode.

This is a strong recommendation based on consensus guidelines.



References:

1. Baugh CW, Levine M, Cornutt D, et al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel. *Ann Emerg Med*. 2020;76(4):470-485. <http://pmid.us/31732375>
2. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2020;76(5):594-622. <http://pmid.us/32680646>
3. Tran H, Joseph J, Young L, et al. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis. *Intern Med J*. 2014;44(6):525-536. <http://pmid.us/24946813>
4. U.S. Food and Drug Administration. *Update on the Safety of Andexxa*. Published December 18, 2025. Accessed January 9, 2026. <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/update-safety-andexxa>
5. Bird SR, Hack K, Kircher JW, Bridwell RE. Traumatic Hyphema with Commotio Retinae in a Special Operations Environment. *J Spec Oper Med*. 2025;24(4):105-108. doi:10.55460/Q09D-3I9E. <https://pubmed.ncbi.nlm.nih.gov/39621006/>
6. Mitrovic D, Folkeringa R, Veeger N, van Roon E. Minor bleeding in patients with atrial fibrillation using a non-vitamin-K antagonist oral anticoagulant. *Curr Med Res Opin*. 2020;36(10):1571-1576. <http://pmid.us/32573287>

Resources for Additional Learning:

Helman A, Himmel W, Douketis J, Bell B. DOACs Part 2: Bleeding and Reversal Agents. *Emergency Medicine Cases*. December 2016. Accessed July 19, 2021.

<https://emergencymedicinecases.com/doacs-bleeding-reversal-agents/>

<https://www.acc.org/Tools-and-Practice-Support/Mobile-Resources/Features/ManageAnticoag>

Kalantari A. Reversing NOACs – Updates for Emergency Physicians. *Emergency Medicine Developments, Oddities, Curiosities (emDOCS)*. Accessed July 19, 2021.

<http://www.emdocs.net/reversing-noacs-updates-emergency-physicians/>

Mahmoud A. A Quick Look at Reversal of Novel Anticoagulants. *Northwestern University Emergency Medicine (NUEM)*. Accessed July 19, 2021. <https://www.nuemblog.com/blog/noac-reversal>

Authors

Rachel Bridwell, MD (Lead)

Editors

Christopher Carpenter, MD; Christopher Edwards, PharmD.; Marianne Gausche-Hill, MD; Stephen Hayden, MD; Samuel Keim, MD, MS; John Marshall, MD, MBA; Ernest Wang, MD